Bone Biologics (BBLG) CFO awarded 8,335 stock options in Form 4

Rhea-AI Filing Summary

Bone Biologics Corp reported an insider equity award for its Chief Financial Officer, Deina Walsh, on a Form 4. On January 8, 2026, she received an employee stock option covering 8,335 shares of common stock with an exercise price of $1.55 per share. According to the filing, this option was granted under the company’s 2015 Equity Incentive Plan and vests and becomes exercisable immediately, with an expiration date of January 8, 2036.

The filing also shows she holds another employee stock option for 4,510 shares at an exercise price of $5.82, which is fully vested and expires on January 15, 2027, as well as 313 shares of common stock held directly after the reported transactions.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Walsh Deina H

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option	8,335	$0.00	--
holding	Employee Stock Option	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Employee Stock Option — 8,335 shares (Direct); Common Stock — 313 shares (Direct)

Footnotes (1)

1. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately. This option is fully vested as of the date of this report.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walsh Deina H

(Last) (First) (Middle)

C/O BONE BIOLOGICS CORP,

2 BURLINGTON WOODS DR. SUITE 100

(Street)

BURLINGTON, MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bone Biologics Corp [ BBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								313	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option	$1.55	01/08/2026		A		8,335		01/08/2026	01/08/2036	Common Stock	8,335(1)	$0	8,335	D
Employee Stock Option	$5.82							(2)	01/15/2027	Common Stock	4,510		4,510	D

Explanation of Responses:

1. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

2. This option is fully vested as of the date of this report.

	/s/ Deina Walsh	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bone Biologics (BBLG) report on this Form 4?

The Form 4 reports that Bone Biologics Corp’s Chief Financial Officer, Deina Walsh, was granted an employee stock option on January 8, 2026, under the company’s 2015 Equity Incentive Plan.

How many Bone Biologics (BBLG) options were granted to the CFO and at what exercise price?

The CFO was granted an option covering 8,335 shares of common stock with an exercise price of $1.55 per share, which vests and becomes exercisable immediately and expires on January 8, 2036.

What other stock options does the Bone Biologics (BBLG) CFO hold after this filing?

After the reported transaction, the CFO holds another employee stock option for 4,510 shares with an exercise price of $5.82 per share, which the filing states is fully vested and expires on January 15, 2027.

How many Bone Biologics (BBLG) common shares does the CFO own directly after the transaction?

The Form 4 shows that the CFO directly owns 313 shares of Bone Biologics common stock following the reported transactions.

Under which plan were the new Bone Biologics (BBLG) options granted to the CFO?

The new option grant for 8,335 shares was made under the Bone Biologics Corporation 2015 Equity Incentive Plan in a transaction described as exempt under Rule 16b-3.

Are the newly granted Bone Biologics (BBLG) options to the CFO immediately exercisable?

Yes. The footnote states that, except as otherwise provided in the award notice, the 8,335-share option vests and becomes exercisable immediately as of the grant on January 8, 2026.